By Ben Hirschler MADRID (Reuters) - Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses. The latest findings will fuel a wider debate about the optimal treatment of melanoma as a new generation of immune-stimulating injections offers an alternative way to fight the deadliest form of skin cancer. ...
via Health News Headlines - Yahoo News http://ift.tt/YBD5hI
No comments:
Post a Comment